Managing refractory metastatic renal cell carcinoma: A RECORD spinning on a tilted AXIS

Clinical Genitourinary Cancer

Volumn 9, Issue 1, 2011, Pages 3-5

  Pal, Sumanta Kumar ^a   Vogelzang, Nicholas J ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; GAMMA INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

CANCER CHEMOTHERAPY; CANCER GROWTH; CLEAR CELL CARCINOMA; DRUG EFFICACY; DRUG INDICATION; DRUG INHIBITION; DRUG SAFETY; DRUG TREATMENT FAILURE; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPOTHYROIDISM; IMMUNOTHERAPY; IN VITRO STUDY; KIDNEY CARCINOMA; NOTE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE MANAGEMENT; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT FAILURE;

EID: 80053040838     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.06.003     Document Type: Note

References (26)

1. National Comprehensive Cancer Network Clinical Practice Guidelines Renal Cell Carcinoma http://www.nccn.org Accessed: May 30, 2011
2. B. Escudier, J. Bellmunt, and S. Négrier Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
3. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134 (Pubitemid 46089673)
4. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
5. R.J. Motzer, B. Escudier, and S. Oudard Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
6. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
7. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 2137-43 J Clin Oncol 28 2010 2137 2143
8. C.N. Sternberg, I.D. Davis, and J. Mardiak Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
9. NCT00720941 Study VEG108844, a Study of Pazopanib Versus Sunitinib in the Treatment of Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma http://www.clinicaltrials.gov Accessed: March 29, 2010
10. R.J. Motzer, B. Escudier, and S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma Cancer 116 2010 4256 4265
11. D.D. Hu-Lowe, H.Y. Zou, and M.L. Grazzini Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3 Clin Cancer Res 14 2008 7272 7283
12. O. Rixe, R.M. Bukowski, and M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
13. R.J. Motzer, T.d.L.M. Rouge, and A.L. Harzstark Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial J Clin Oncol 29 Suppl 2011 Abstract 4547
14. B.I. Rini, G. Wilding, and G. Hudes Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
15. B.I. Rini, B. Escudier, and P. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial J Clin Oncol 29 Suppl 2011 Abstract 4503
16. D. Cella, B. Escudier, and B.I. Rini Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 Suppl 2011 Abstract 4504
17. J.L. Beaumont, Z. Butt, and J. Baladi Patient-reported outcomes in a phase III study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy Oncologist 16 2011 632 640
18. NCT01064310 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment nave Locally Advanced or Metastatic Renal Cell Carcinoma http://www.clinicaltrials.gov Accessed: March 29, 2010
19. NCT00474786 A Randomized Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy http://www.clinicaltrials.gov Accessed: March 12, 2010
20. D.Y. Heng, M.J. MacKenzie, and U.N. Vaishampayan Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy Genitourinary Cancers Symposium 2011 Abstract 305
21. FDA Approval Letter for Sorafenib http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2005/021923ltr.pdf Accessed: March 24, 2010
22. FDA Approval Letter for Sunitinib http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2006/021968s000ltr.pdf Accessed: March 24, 2010
23. FDA News Release: Bevacizumab in Combination with Interferon Alfa http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm176025.htm Accessed: June 1, 2011
24. FDA News Release: Temsirolimus http://www.fda.gov/AboutFDA/ CentersOffices/CDER/ucm129247.htm Accessed: June 1, 2011
25. FDA News Release: Pazopanib http://www.fda.gov/AboutFDA/CentersOffices/ CDER/ucm187509.htm Accessed: June 1, 2011
26. Afinitor [prescribing information] http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/022334s6lbl.pdf Accessed: June 1, 2011